Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Akcea Therapeutics, Inc. (NASDAQ: AKCA).

Full DD Report for AKCA

You must become a subscriber to view this report.


Recent News from (NASDAQ: AKCA)

Akcea to axe 10% of workforce
Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) discloses that it intends to cut 10% of its workforce as part of its reorganization plan following the FDA's rejection of its WAYLIVRA ( volanesorsen) marketing application. It expects to record a charge of ...
Source: SeekingAlpha
Date: September, 06 2018 16:38
A Second Look At Inotersen's Approval Potential
Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Last week, Io...
Source: SeekingAlpha
Date: September, 04 2018 17:46
Stocks To Watch: Time To Talk Valuation
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The stock market could get a bit of a test as traders return back to their desks fo...
Source: SeekingAlpha
Date: September, 01 2018 08:28
Alnylam's patisiran OK'd in Europe for hATTR amyoidosis
The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,...
Source: SeekingAlpha
Date: August, 30 2018 07:42
Ionis Pharmaceuticals Receives CRL From FDA, But This Was Just A Minor Setback
Ionis Pharmaceuticals ( IONS ) and Akcea Therapeutics ( AKCA ) announced that the FDA has rejected volanesorsen to treat patients with familial chylomicronemia syndrome ((FCS)). FCS is a disease that is associated with high levels of triglycerides . This FDA rejection was shocking, but ...
Source: SeekingAlpha
Date: August, 29 2018 11:52
Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference
CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.(NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company overview at the Wells Fargo Healthcare Conference at 4:10 p.m. ET on Wednesday, September 5, 2018 in...
Source: GlobeNewswire
Date: August, 29 2018 07:00
Midday Gainers / Losers (08/28/2018)
Gainers: AFMD +220% . ATAI +43% . STAF +30% . ASFI +26% . BRKS +27% . VVPR +19% . DSW +18% . CVM +17% . BILI +16% . ABIL +15% . More news on: Affimed Therapeutics, ATA Inc., Staffing 360 Solutions, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 28 2018 12:45
Approval, Labeling, Pricing, And Competitor Data All Give Alnylam Pharmaceuticals A Wild Ride
It’s been an interesting period of time to be an Alnylam ( ALNY ) shareholder, as the company got its first FDA approval (Onpattro), but with a narrower label than hoped and a somewhat confusing price structure. On top of that, a key potential competitor that wasn’t even seen a...
Source: SeekingAlpha
Date: August, 28 2018 12:21
Premarket Losers as of 9:05 am (8/28/2018)
AKCA   -28%  after FDA rejection of volanesorsen. More news on: Akcea Therapeutics, Ionis Pharmaceuticals, Inc., India Globalization Capital, Inc, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 28 2018 09:09
Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA
CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced that they received a Complete Response Letter (CRL) from the ...
Source: GlobeNewswire
Date: August, 27 2018 16:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0825.4826.1726.8724.5178368,835
2018-05-1722.7122.9323.01522.64142,101

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1726,00246,74755.6228Short
2018-12-1438,00244,78184.8619Short
2018-12-1317,16725,68866.8289Short
2018-12-1215,33642,83835.8000Short
2018-12-1139,58152,50575.3852Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AKCA.


About Akcea Therapeutics, Inc. (NASDAQ: AKCA)

Logo for Akcea Therapeutics, Inc. (NASDAQ: AKCA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AKCA)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 26 2018
      All other definitive information statements
      Filing Type: DEF 14CFiling Source: edgar
      Filing Date: April, 20 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 20 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 06 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: March, 28 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: March, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: AKCA)

      Daily Technical Chart for (NASDAQ: AKCA)


      Stay tuned for daily updates and more on (NASDAQ: AKCA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AKCA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKCA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AKCA and does not buy, sell, or trade any shares of AKCA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/